C3 GLOMERULOPATHY
Clinical trials for C3 GLOMERULOPATHY explained in plain language.
Never miss a new study
Get alerted when new C3 GLOMERULOPATHY trials appear
Sign up with your email to follow new studies for C3 GLOMERULOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug survey for rare kidney disease: is fabhalta the answer?
Disease control Recruiting nowThis study is tracking 50 people with C3 glomerulopathy, a rare kidney disease, who are taking the drug Fabhalta. Researchers want to see how safe the drug is and how well it controls the disease in everyday medical practice. The study will monitor infections, side effects, and k…
Matched conditions: C3 GLOMERULOPATHY
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 06:15 UTC
-
New drug aims to protect kidneys in rare disease patients for years
Disease control Recruiting nowThis study is testing the long-term safety and effectiveness of a daily oral drug called iptacopan for people with rare kidney diseases (C3G and IC-MPGN). It will follow up to 225 patients who have already been taking the drug in earlier studies, tracking their kidney function an…
Matched conditions: C3 GLOMERULOPATHY
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 13, 2026 20:19 UTC